Trade-Ideas LLC identified Celgene Corporation (NASDAQ:CELG) as a “roof leaker” (crossing below the 200-day simple moving average on higher than normal relative volume) candidate. Celgene Corporation (NASDAQ:CELG) shares after opening at $154.28 moved to $155.28 on last trade day and at the end of the day closed at $149.41. Company price to sales ratio in past twelve months was calculated as 9.46 and price to cash ratio as 10.80. Celgene Corporation (NASDAQ:CELG) showed a negative weekly performance of -4.57%.
Merck & Co Inc. (NYSE:MRK) which makes Zilmax and Elanco Animal Health, which makes ractopamine, criticized the researchers’ methodology and noted that the feed additives are approved by the Food and Drug Administration. Merck & Co., Inc. (NYSE:MRK) shares fell -0.16% in last trading session and ended the day on $55.70. MRK return on equity ratio is recorded as 12.10% and its return on assets is 5.60%. Merck & Co., Inc. (NYSE:MRK) yearly performance is 30.29%.
Bristol-Myers Squibb (NYSE:BMY) and Pfizer are ending their work week on a high note. The latterannounced that a Supplemental New Drug application for the medication they developed together, Eliquis, has been conditionally approved by the Food and Drug Administration. Bristol-Myers Squibb Co (NYSE:BMY) shares moved down -0.33% in last trading session and was closed at $54.00 while trading in range of $53.88 – $54.44 – Bristol-Myers Squibb Co (NYSE:BMY) year to date (YTD) performance is 1.60%.
ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) is a global oncology company focused on the discovery, development and commercialization of medicines for the cancer patients. ARIAD’s first medicine, Iclusig, is approved in the United States for the treatment of adult patients with chronic, accelerated or blast phase chronic myeloid leukemia that is resistant or intolerant to prior tyrosine kinase inhibitor (TKI) therapy or Philadelphia chromosome-positive acute lymphoblastic leukemia that is resistant or intolerant to prior TKI therapy. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) weekly performance is 0.49%. On last trading day company shares ended up $8.17. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) distance from 50-day simple moving average (SMA50) is 5.65%. Analysts mean target price for the company is $8.56.
Leave a Reply